
Today on Drug Discovery & Development
FDA approved Inovio’s Voceryq with open questions about its delivery device
The FDA has asked Inovio Pharmaceuticals, a company developing DNA-based medicines, to reanalyze its human factors testing of the Cellectra 5PSP, the electroporation device that delivers its newly approved drug Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), a pioneering plasmid DNA-based immunotherapy. The agency is also asking it to verify the device’s sharps injury prevention feature.…If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Drug prices are one of the few issues on which Donald Trump has found common ground with progressive Democrats, and with voters in both parties. A March 2026 KFF poll found that 72% of adults say there is not enough government regulation limiting drug prices, including 77% of Democrats, 72% of independents and 68% of…Drug Discovery and Development See More >

2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
The Arlington, Virginia–based nonprofit American Association of Pharmaceutical Scientists (AAPS) will launch two Innovator-Curated tracks at its 2026 PharmSci 360 conference, scheduled for October 25–28, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The organization announced that the tracks will explore the current state of scientific research integrity in an AI…

FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide

As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%

Sai Life Sciences’ bet on information-dense scale-up and how it is responding to pharma clients who want acceleration

Ahead of PharmSci 360, DigiM CEO on turning hidden microstructures into drug-release predictions
Sponsored Content See More >
Genomics/Proteomics See More >

New cell imaging method reveals hidden enzyme activity
Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…

Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification

Spatial biology: Transforming our understanding of cellular environments

Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Infectious Disease See More >

Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice
The COVID-19 pandemic left most of the world’s population with an immune memory for COVID. A Cleveland-based biotech wants to use that memory to fight cancer. Celloram, a preclinical stage company focusing on therapies for cancer, autoimmune diseases and chronic inflammatory and metabolic disorders, in partnership with Case Western Reserve University and University Hospitals Cleveland Medical Center, published preclinical results for a…

AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.

FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life

As measles cases hit a 35-year high, Trump executive order backs a narrower childhood vaccine list

AbbVie’s Maviret ends the wait-and-see reality for acute HCV
Oncology See More >

What real-world data shows about current cancer care
Only about 5% of adult cancer patients join clinical trials. Experts explain how real-world data fills gaps and what makes it representative and reliable.

Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront

After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice

Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice

























